PINK
MKGAF

MERCK Kommanditgesellschaft auf Aktien

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

MERCK Kommanditgesellschaft auf Aktien Stock Price

Vitals

Today's Low:
$172.76
Today's High:
$180.04
Open Price:
$172.76
52W Low:
$146.3999
52W High:
$216.0719
Prev. Close:
$178.15
Volume:
162

Company Statistics

Market Cap.:
$76.88 billion
Book Value:
61.443
Revenue TTM:
$22.06 billion
Operating Margin TTM:
21.15%
Gross Profit TTM:
$13.74 billion
Profit Margin:
13.95%
Return on Assets TTM:
5.98%
Return on Equity TTM:
11.71%

Company Profile

MERCK Kommanditgesellschaft auf Aktien had its IPO on under the ticker symbol MKGAF.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. MERCK Kommanditgesellschaft auf Aktien has a staff strength of 63,712 employees.

Stock update

Shares of MERCK Kommanditgesellschaft auf Aktien opened at $172.76 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $172.76 - $180.04, and closed at $178.5.

This is a +0.2% increase from the previous day's closing price.

A total volume of 162 shares were traded at the close of the day’s session.

In the last one week, shares of MERCK Kommanditgesellschaft auf Aktien have slipped by -1.11%.

MERCK Kommanditgesellschaft auf Aktien's Key Ratios

MERCK Kommanditgesellschaft auf Aktien has a market cap of $76.88 billion, indicating a price to book ratio of 2.7492 and a price to sales ratio of 3.7627.

In the last 12-months MERCK Kommanditgesellschaft auf Aktien’s revenue was $22.06 billion with a gross profit of $13.74 billion and an EBITDA of $6.23 billion. The EBITDA ratio measures MERCK Kommanditgesellschaft auf Aktien's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, MERCK Kommanditgesellschaft auf Aktien’s operating margin was 21.15% while its return on assets stood at 5.98% with a return of equity of 11.71%.

In Q2, MERCK Kommanditgesellschaft auf Aktien’s quarterly earnings growth was a negative -18.6% while revenue growth was a negative 4.8%.

MERCK Kommanditgesellschaft auf Aktien’s PE and PEG Ratio

Forward PE
16.4204
Trailing PE
23.5178
PEG
3.0673

Its diluted EPS in the last 12-months stands at $7.59 per share while it has a forward price to earnings multiple of 16.4204 and a PEG multiple of 3.0673. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into MERCK Kommanditgesellschaft auf Aktien’s profitability.

MERCK Kommanditgesellschaft auf Aktien stock is trading at a EV to sales ratio of 4.2334 and a EV to EBITDA ratio of 14.0096. Its price to sales ratio in the trailing 12-months stood at 3.7627.

MERCK Kommanditgesellschaft auf Aktien stock pays annual dividends of $2.2 per share, indicating a yield of 1.36% and a payout ratio of 27.72%.

Balance sheet and cash flow metrics

Total Assets
$48.78 billion
Total Liabilities
$8.85 billion
Operating Cash Flow
$0
Capital Expenditure
$327 million
Dividend Payout Ratio
27.72%

MERCK Kommanditgesellschaft auf Aktien ended 2024 with $48.78 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $48.78 billion while shareholder equity stood at $26.70 billion.

MERCK Kommanditgesellschaft auf Aktien ended 2024 with $0 in deferred long-term liabilities, $8.85 billion in other current liabilities, 565000000.00 in common stock, $19.76 billion in retained earnings and $18.10 billion in goodwill. Its cash balance stood at $1.76 billion and cash and short-term investments were $1.93 billion. The company’s total short-term debt was $1,690,000,000 while long-term debt stood at $0.

MERCK Kommanditgesellschaft auf Aktien’s total current assets stands at $13.02 billion while long-term investments were $0 and short-term investments were $166.00 million. Its net receivables were $4.85 billion compared to accounts payable of $2.40 billion and inventory worth $5.00 billion.

In 2024, MERCK Kommanditgesellschaft auf Aktien's operating cash flow was $0 while its capital expenditure stood at $327 million.

Comparatively, MERCK Kommanditgesellschaft auf Aktien paid $0.28 in dividends in 2024.

Other key metrics

Current Trading Price
$178.5
52-Week High
$216.0719
52-Week Low
$146.3999
Analyst Target Price
$

MERCK Kommanditgesellschaft auf Aktien stock is currently trading at $178.5 per share. It touched a 52-week high of $216.0719 and a 52-week low of $216.0719. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $173.01 and 200-day moving average was $181.99 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 5795.8% are held by institutions.

Frequently Asked Questions About MERCK Kommanditgesellschaft auf Aktien

The stock symbol (also called stock or share ticker) of MERCK Kommanditgesellschaft auf Aktien is MKGAF

The IPO of MERCK Kommanditgesellschaft auf Aktien took place on

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
$62.38
-6.62
-9.59%
$155.74
1
+0.65%
$3.02
0.08
+2.72%
$557.75
-29.3
-4.99%
$21.99
0.97
+4.61%
$0
-0
-24.24%
$4.18
-0.46
-9.91%
$2772.35
-32.55
-1.16%
$79.98
1.98
+2.54%
$12.83
0.14
+1.1%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Merck KGaA operates as a science and technology company in Germany. The company’s Life Science segment offers a range of products, including reagents, consumable, devices, instruments, software, and services for scientific discovery, as well as provides lab water instruments, consumables and services, microbiology and biomonitoring, products, test assays, analytical reagents, and flow cytometry kits and instruments for pharma and biotech, industrial and testing, academics and government, and diagnostic sectors. Its Healthcare segment designs and develops medicines and intelligent devices for treatment of various therapeutics, such as oncology, neurology and immunology, endocrinology, and general medicines. The company’s Electronic segment provides semiconductor solutions, such as semiconductor materials, delivery systems and services, and intermolecular services for semiconductor and polymer removal chemistries applications; and display solutions comprising liquid crystals, OLED and quantum materials, reactive mesogens, photoresist materials, smart antenna, and dynamic liquid crystal glazing products, as well as offers liviFlex, a flexible platform, which offers a range of display materials. This segment also provides surface solution, such as cosmetics, effect pigments, and functional solutions; architecture solutions, including switchable windows; and automotive solutions. In addition, it has strategic alliances with Pfizer Inc. and GlaxoSmihKline plc to develop and commercialize active ingredients in immune-oncology; in-licensing agreement with Debiopharm International SA for developing drug candidates for the treatment of head and neck cancer; and out-licensing agreement with MoonLake Immunotherapeutics AG for developing a drug candidate for the treatment of inflammatory diseases. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Address

Frankfurter Strasse 250, Darmstadt, Germany, 64293